Lee Minji K, Mitchell Sandra A, Basch Ethan, Mazza Gina L, Langlais Blake T, Thanarajasingam Gita, Ginos Brenda F, Rogak Lauren, Meek Eric A, Jansen Jennifer, Deal Allison M, Carr Philip, Blinder Victoria S, Jonsson Mattias, Mody Gita N, Mendoza Tito R, Bennett Antonia V, Schrag Deborah, Dueck Amylou C
Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, 200 1st Ave SW, Rochester, MN, 55902, USA.
National Cancer Institute, Bethesda, MD, USA.
Qual Life Res. 2025 Feb;34(2):495-507. doi: 10.1007/s11136-024-03819-5. Epub 2024 Nov 6.
We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores.
We used two data sources, the PRO-TECT trial (Alliance AFT-39) that collected PRO-CTCAE data from adults with advanced cancer at 26 United States (U.S.) community oncology practices and the PRO-CTCAE validation study that collected PRO-CTCAE data from adults undergoing chemotherapy or radiation therapy at nine U.S. cancer centers or community oncology practices. Both studies administered selected PRO-CTCAE items and EORTC QLQ-C30 scales. Conceptually, relevant QLQ-C30 domains were used as anchors to estimate meaningful change thresholds for deterioration in corresponding PRO-CTCAE items and their composite scores. Items or composites with ǀρǀ ≥ 0.30 correlation with QLQ-C30 scales were included. Changes in PRO-CTCAE scores and composites were estimated for patients who met or exceeded a 10-point deterioration on the corresponding QLQ-C30 scale. Change scores were computed between baseline and the 3-month timepoint in PRO-TECT, and in the PRO-CTCAE validation study between baseline and a single follow-up visit that occurred between 1 and 7 weeks later. For each PRO-CTCAE item, change scores could range from - 4 to 4; for a composite, change scores could range from - 3 to 3.
Change scores in QLQ-C30 and PRO-CTCAE were available in 406 and 792 patients in PRO-TECT and the validation study, respectively. Across QLQ-C30 scales, the proportion of patients with a 10-point or greater worsening on QLQ-C30 ranged from 15 to 30% in the PRO-TECT data and 13% to 34% in the validation data. Across PRO-CTCAE items, anchor-based meaningful change estimates for deterioration ranged from 0.05 to 0.30 (mean 0.19) in the PRO-TECT data and from 0.19 to 0.53 (mean 0.36) in the validation data. For composites, they ranged from 0.06 to 0.27 (mean 0.17) in the PRO-TECT data and 0.22 to 0.51 (mean 0.37) in the validation data.
In both datasets, the minimal meaningful individual-level change threshold for worsening was one point for all items and composite scores.
gov: NCT03249090 (AFT-39), NCT02158637 (MC1091).
我们得出了选定的患者报告的不良事件通用术语标准(PRO-CTCAE®)项目及其综合评分恶化的有意义的个体水平变化阈值。
我们使用了两个数据源,即PRO-TECT试验(联盟AFT-39),该试验从美国26个社区肿瘤学实践机构的晚期癌症成人患者中收集PRO-CTCAE数据,以及PRO-CTCAE验证研究,该研究从美国9个癌症中心或社区肿瘤学实践机构接受化疗或放疗的成人患者中收集PRO-CTCAE数据。两项研究均采用了选定的PRO-CTCAE项目和欧洲癌症研究与治疗组织QLQ-C30量表。从概念上讲,相关的QLQ-C30领域被用作锚点,以估计相应PRO-CTCAE项目及其综合评分恶化的有意义变化阈值。纳入与QLQ-C30量表相关性|ρ|≥0.30的项目或综合评分。对在相应QLQ-C30量表上达到或超过10分恶化的患者,估计其PRO-CTCAE评分和综合评分的变化。在PRO-TECT试验中,计算基线与3个月时间点之间的变化分数,在PRO-CTCAE验证研究中,计算基线与1至7周后进行的单次随访之间的变化分数。对于每个PRO-CTCAE项目,变化分数范围为-4至4;对于综合评分,变化分数范围为-3至3。
在PRO-TECT试验和验证研究中,分别有406例和792例患者获得了QLQ-C30和PRO-CTCAE的变化分数。在QLQ-C30量表中,在PRO-TECT数据中,QLQ-C30恶化10分或以上的患者比例为15%至30%,在验证数据中为13%至34%。在PRO-TECT数据中,基于锚点的恶化有意义变化估计值在0.05至0.30之间(平均0.19),在验证数据中为0.19至0.53之间(平均0.36)。对于综合评分,在PRO-TECT数据中,其范围为0.06至0.27(平均0.17),在验证数据中为0.22至0.51(平均0.37)。
在两个数据集中,所有项目和综合评分恶化的最小有意义个体水平变化阈值均为1分。
gov:NCT03249090(AFT-39),NCT02158637(MC1091)。